133 results on '"Van den Abbeele, Pieter"'
Search Results
102. Arabinoxylans and inulin modulate the luminal and mucosa-associated bacteria in vitro and in vivo
- Author
-
Van den Abbeele, Pieter, Van De Wiele, Tom, Grootaert, Charlotte, Verstraete, Willy, Gerard, Philippe, Bruneau, Aurelia, Rabot, Sylvie, Possemiers, Sam, LabMET, Universiteit Gent = Ghent University [Belgium] (UGENT), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, J.W. Vanderkamp, J. Jones, B. McCleary, D. Topping, and Ghent University [Belgium] (UGENT)
- Subjects
mucus ,prebiotic index ,[SDV]Life Sciences [q-bio] ,microbiota ,gut ,gnotobiotic rats - Abstract
4. International Dietary Fibre Conference. Vienne. 2009/07/01-03; There is increasing interest in gastro-intestinal microbiology to improve the balance between putative beneficial and harmful commensal microbiota. Mucosal microbes make closer contact with the host than luminal ones and could therefore more strongly affect host health. A short term in vitro adhesion assay was used to examine initial mucin colonisation by bacteria derived from the mixed microbial community of the ascending colon of the Simulator of the Human Intestinal Microbial Ecosystem (SHIME). Further, long term prebiotic effects on the luminal and mucosa-associated microbial community (MAMC) were assessed in vitro and in vivo with respectively the SHIME and gnotobiotic rats. During the short term experiment, adhesion capacity differed substantially between bacteria and decreased from lactobacilli over faecal coliforms, bifidobacteria and clostridia to total anaerobes. In addition, intestinal water lowered adhesion compared to phosphate buffered saline. By processing the data to an Adhesion Related Prebiotic Index (AR-PI), it was found that intestinal water stimulated adherence of positive commensals. Arabinoxylans (AX) decreased the bacterial adhesion capacity (matrix independently), whereas inulin had less or no influence. During the long term experiment, group-specific DGGE analysis showed that although inoculated with the same human faecal microbiota, the in vivo and in vitro model both harbour distinct microbial communities. Both carbohydrates were shown to exert long term prebiotic effects on the luminal and mucosal microbial community. Interestingly, AX induced a shift towards a specific Bifidobacterium sp, both in the in vitro and in vivo model. The developed methodologies could be useful for the characterisation of the relevant but barely investigated mucosa-associated microbial community in health and disease (e.g. IBD) as well as for its modulation with functional foods like prebiotics.
- Published
- 2010
103. The HMI™ module: a new tool to study the Host-Microbiota Interaction in the human gastrointestinal tract in vitro
- Author
-
Marzorati, Massimo, primary, Vanhoecke, Barbara, additional, De Ryck, Tine, additional, Sadaghian Sadabad, Mehdi, additional, Pinheiro, Iris, additional, Possemiers, Sam, additional, Van den Abbeele, Pieter, additional, Derycke, Lara, additional, Bracke, Marc, additional, Pieters, Jan, additional, Hennebel, Tom, additional, Harmsen, Hermie J, additional, Verstraete, Willy, additional, and Van de Wiele, Tom, additional
- Published
- 2014
- Full Text
- View/download PDF
104. Synthetic microbial ecosystems: an exciting tool to understand and apply microbial communities
- Author
-
De Roy, Karen, primary, Marzorati, Massimo, additional, Van den Abbeele, Pieter, additional, Van de Wiele, Tom, additional, and Boon, Nico, additional
- Published
- 2013
- Full Text
- View/download PDF
105. Different Human Gut Models Reveal the Distinct Fermentation Patterns of Arabinoxylan versus Inulin
- Author
-
Van den Abbeele, Pieter, primary, Venema, Koen, additional, Van de Wiele, Tom, additional, Verstraete, Willy, additional, and Possemiers, Sam, additional
- Published
- 2013
- Full Text
- View/download PDF
106. A Dried Yeast Fermentate Selectively Modulates both the Luminal and Mucosal Gut Microbiota and Protects against Inflammation, As Studied in an Integrated in Vitro Approach
- Author
-
Possemiers, Sam, primary, Pinheiro, Iris, additional, Verhelst, An, additional, Van den Abbeele, Pieter, additional, Maignien, Lois, additional, Laukens, Debby, additional, Reeves, Stuart G., additional, Robinson, Larry E., additional, Raas, Thomas, additional, Schneider, Yves-Jacques, additional, Van de Wiele, Tom, additional, and Marzorati, Massimo, additional
- Published
- 2013
- Full Text
- View/download PDF
107. Prebiotics, faecal transplants and microbial network units to stimulate biodiversity of the human gut microbiome
- Author
-
Van den Abbeele, Pieter, primary, Verstraete, Willy, additional, El Aidy, Sahar, additional, Geirnaert, Annelies, additional, and Van de Wiele, Tom, additional
- Published
- 2013
- Full Text
- View/download PDF
108. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model
- Author
-
Van den Abbeele, Pieter, primary, Belzer, Clara, additional, Goossens, Margot, additional, Kleerebezem, Michiel, additional, De Vos, Willem M, additional, Thas, Olivier, additional, De Weirdt, Rosemarie, additional, Kerckhof, Frederiek-Maarten, additional, and Van de Wiele, Tom, additional
- Published
- 2012
- Full Text
- View/download PDF
109. Incorporating a mucosal environment in a dynamic gut model results in a more representative colonization by lactobacilli
- Author
-
Van den Abbeele, Pieter, primary, Roos, Stefan, additional, Eeckhaut, Venessa, additional, MacKenzie, Donald A., additional, Derde, Melanie, additional, Verstraete, Willy, additional, Marzorati, Massimo, additional, Possemiers, Sam, additional, Vanhoecke, Barbara, additional, Van Immerseel, Filip, additional, and Van de Wiele, Tom, additional
- Published
- 2011
- Full Text
- View/download PDF
110. The host selects mucosal and luminal associations of coevolved gut microorganisms: a novel concept
- Author
-
Van den Abbeele, Pieter, primary, Van de Wiele, Tom, additional, Verstraete, Willy, additional, and Possemiers, Sam, additional
- Published
- 2011
- Full Text
- View/download PDF
111. Microbial Community Development in a Dynamic Gut Model Is Reproducible, Colon Region Specific, and Selective for Bacteroidetes and Clostridium Cluster IX
- Author
-
Van den Abbeele, Pieter, primary, Grootaert, Charlotte, additional, Marzorati, Massimo, additional, Possemiers, Sam, additional, Verstraete, Willy, additional, Gérard, Philippe, additional, Rabot, Sylvie, additional, Bruneau, Aurélia, additional, El Aidy, Sahar, additional, Derrien, Muriel, additional, Zoetendal, Erwin, additional, Kleerebezem, Michiel, additional, Smidt, Hauke, additional, and Van de Wiele, Tom, additional
- Published
- 2010
- Full Text
- View/download PDF
112. Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem
- Author
-
Grootaert, Charlotte, primary, Van den Abbeele, Pieter, additional, Marzorati, Massimo, additional, Broekaert, Willem F., additional, Courtin, Christophe M., additional, Delcour, Jan A., additional, Verstraete, Willy, additional, and Van de Wiele, Tom, additional
- Published
- 2009
- Full Text
- View/download PDF
113. Interindividual differences in response to treatment with butyrate-producing Butyricicoccus pullicaecorum 25-3T studied in an in vitro gut model.
- Author
-
Geirnaert, Annelies, Jun Wang, Tinck, Magali, Steyaert, Alix, Van den Abbeele, Pieter, Eeckhaut, Venessa, Vilchez-Vargas, Ramiro, Falony, Gwen, Laukens, Debby, De Vos, Martine, Van Immerseel, Filip, Raes, Jeroen, Boon, Nico, and Van de Wiele, Tom
- Subjects
BUTYRATES ,BUTYRIC acid ,GASTROINTESTINAL diseases ,MICROORGANISMS ,MICROBIOLOGY - Abstract
Butyrate-producing bacteria are promising probiotic candidates to target microbial dysbiosis in gastrointestinal disorders like inflammatory bowel diseases. Butyricicoccus pullicaecorum 25-3
T , a butyrate-producing clostridial cluster IV strain, is such a candidate. Little is known about its abundance in the colon microbiota and its butyrogenic properties. We used the M-SHIMER® , an in vitro simulator for the human intestinal microbial ecosystem, to study the effect of supplementing a single dose of B. pullicaecorum 25-3T on lumen- and mucus-associated microbiota of eight individuals. Butyricicoccus pullicaecorum was more abundant in mucus-associated microbiota compared with lumen microbiota. Supplementation with a single dose of B. pullicaecorum 25-3T resulted in a temporary increase in B. pullicaecorum bacteria in lumen compartment of all individuals. In two cases, the responders, an increased butyrate production was observed as compared with the control. 16S rRNA gene amplicon sequencing revealed the microbiota of responders to be different as compared to non-responder microbiota. We can conclude that B. pullicaecorum 25-3T is a mucus-associated bacterium whose potency to stimulate butyrate production is characterized by a large interindividual variability in terms of composition of the receiving microbial community. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
114. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model.
- Author
-
Van den Abbeele, Pieter, Belzer, Clara, Goossens, Margot, Kleerebezem, Michiel, De Vos, Willem M, Thas, Olivier, De Weirdt, Rosemarie, Kerckhof, Frederiek-Maarten, and Van de Wiele, Tom
- Subjects
- *
BUTYRATES , *CLOSTRIDIUM , *COLONIZATION (Ecology) , *MUCINS , *GUT microbiome , *BACTEROIDES , *PROTEOBACTERIA , *COA transferases - Abstract
The human gut is colonized by a complex microbiota with multiple benefits. Although the surface-attached, mucosal microbiota has a unique composition and potential to influence human health, it remains difficult to study in vivo. Therefore, we performed an in-depth microbial characterization (human intestinal tract chip (HITChip)) of a recently developed dynamic in vitro gut model, which simulates both luminal and mucosal gut microbes (mucosal-simulator of human intestinal microbial ecosystem (M-SHIME)). Inter-individual differences among human subjects were confirmed and microbial patterns unique for each individual were preserved in vitro. Furthermore, in correspondence with in vivo studies, Bacteroidetes and Proteobacteria were enriched in the luminal content while Firmicutes rather colonized the mucin layer, with Clostridium cluster XIVa accounting for almost 60% of the mucin-adhered microbiota. Of the many acetate and/or lactate-converting butyrate producers within this cluster, Roseburia intestinalis and Eubacterium rectale most specifically colonized mucins. These 16S rRNA gene-based results were confirmed at a functional level as butyryl-CoA:acetate-CoA transferase gene sequences belonged to different species in the luminal as opposed to the mucin-adhered microbiota, with Roseburia species governing the mucosal butyrate production. Correspondingly, the simulated mucosal environment induced a shift from acetate towards butyrate. As not only inter-individual differences were preserved but also because compared with conventional models, washout of relevant mucin-adhered microbes was avoided, simulating the mucosal gut microbiota represents a breakthrough in modeling and mechanistically studying the human intestinal microbiome in health and disease. Finally, as mucosal butyrate producers produce butyrate close to the epithelium, they may enhance butyrate bioavailability, which could be useful in treating diseases, such as inflammatory bowel disease. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
115. Consistent Prebiotic Effects of Carrot RG-I on the Gut Microbiota of Four Human Adult Donors in the SHIME ® Model despite Baseline Individual Variability.
- Author
-
Van den Abbeele, Pieter, Duysburgh, Cindy, Cleenwerck, Ilse, Albers, Ruud, Marzorati, Massimo, and Mercenier, Annick
- Subjects
HUMAN microbiota ,HUMAN biology ,GUT microbiome ,DEVELOPMENTAL biology ,PECTINS ,BIFIDOBACTERIUM longum ,CARROTS ,BUTYRATES - Abstract
The human gut microbiome is currently recognized to play a vital role in human biology and development, with diet as a major modulator. Therefore, novel indigestible polysaccharides that confer a health benefit upon their fermentation by the microbiome are under investigation. Based on the recently demonstrated prebiotic potential of a carrot-derived pectin extract enriched for rhamnogalacturonan I (cRG-I), the current study aimed to assess the impact of cRG-I upon repeated administration using the M-SHIME technology (3 weeks at 3g cRG-I/d). Consistent effects across four simulated adult donors included enhanced levels of acetate (+21.1 mM), propionate (+17.6 mM), and to a lesser extent butyrate (+4.1 mM), coinciding with a marked increase of OTUs related to Bacteroides dorei and Prevotella species with versatile enzymatic potential likely allowing them to serve as primary degraders of cRG-I. These Bacteroidetes members are able to produce succinate, explaining the consistent increase of an OTU related to the succinate-converting Phascolarctobacterium faecium (+0.47 log
10 (cells/mL)). While the Bifidobacteriaceae family remained unaffected, a specific OTU related to Bifidobacterium longum increased significantly upon cRG-I treatment (+1.32 log10 (cells/mL)). Additional monoculture experiments suggested that Bifidobacterium species are unable to ferment cRG-I structures as such and that B. longum probably feeds on arabinan and galactan side chains of cRG-I, released by aforementioned Bacteroidetes members. Overall, this study confirms the prebiotic potential of cRG-I and additionally highlights the marked consistency of the microbial changes observed across simulated subjects, suggesting the involvement of a specialized consortium in cRG-I fermentation by the human gut microbiome. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
116. A Long-Chain Dextran Produced by Weissella cibaria Boosts the Diversity of Health-Related Gut Microbes Ex Vivo.
- Author
-
Tintoré, Maria, Cuñé, Jordi, Vu, Lam Dai, Poppe, Jonas, Van den Abbeele, Pieter, Baudot, Aurélien, and de Lecea, Carlos
- Subjects
- *
DEXTRAN , *BUTYRATES , *BETA-glucans , *MICROBIAL diversity , *GUT microbiome , *REGULATION of body weight - Abstract
Simple Summary: Conventional diversity metrics do not fully capture treatment impacts on microbial diversity. An innovative community modulation score (CMS), coupled with the predictive SIFR® technology, underlined the potential of a bacterial long-chain dextran as a booster of microbial diversity, as compared to the well-established prebiotic inulin. Long-chain dextrans are α-glucans that can be produced by lactic acid bacteria. NextDextTM, a specific long-chain dextran with a high degree of polymerisation, produced using Weissella cibaria, was recently shown to exert prebiotic potential in vitro. In this study, the ex vivo SIFR® technology, recently validated to provide predictive insights into gut microbiome modulation down to the species level, was used to investigate the effects of this long-chain dextran on the gut microbiota of six human adults that altogether covered different enterotypes. A novel community modulation score (CMS) was introduced based on the strength of quantitative 16S rRNA gene sequencing and the highly controlled ex vivo conditions. This CMS overcomes the limitations of traditional α-diversity indices and its application in the current study revealed that dextran is a potent booster of microbial diversity compared to the reference prebiotic inulin (IN). Long-chain dextran not only exerted bifidogenic effects but also consistently promoted Bacteroides spp., Parabacteroides distasonis and butyrate-producing species like Faecalibacterium prausnitzii and Anaerobutyricum hallii. Further, long-chain dextran treatment resulted in lower gas production compared to IN, suggesting that long-chain dextran could be better tolerated. The additional increase in Bacteroides for dextran compared to IN is likely related to the higher propionate:acetate ratio, attributing potential to long-chain dextran for improving metabolic health and weight management. Moreover, the stimulation of butyrate by dextran suggests its potential for improving gut barrier function and inflammation. Overall, this study provides a novel tool for assessing gut microbial diversity ex vivo and positions long-chain dextran as a substrate that has unique microbial diversity enhancing properties. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
117. A randomized, placebo-controlled trial investigating the acute and chronic benefits of American Ginseng (Cereboost®) on mood and cognition in healthy young adults, including in vitro investigation of gut microbiota changes as a possible mechanism of action
- Author
-
Bell, Lynne, Whyte, Adrian, Duysburgh, Cindy, Marzorati, Massimo, Van den Abbeele, Pieter, Le Cozannet, Romain, Fança-Berthon, Pascale, Fromentin, Emilie, and Williams, Claire
- Subjects
- *
IN vitro studies , *AFFECT (Psychology) , *COLON (Anatomy) , *GUT microbiome , *COGNITION , *INGESTION , *TREATMENT duration , *TASK performance , *DIETARY supplements , *RANDOMIZED controlled trials , *PLACEBOS , *COMPARATIVE studies , *ACETYLCHOLINE , *PROPIONATES , *DOSE-effect relationship in pharmacology , *BLIND experiment , *SHORT-term memory , *ATTENTION , *ACETIC acid , *REACTION time , *LACTOBACILLUS , *GINSENG , *MENTAL fatigue , *BUTYRIC acid , *SHORT-chain fatty acids , *ADULTS , *ADOLESCENCE - Abstract
Purpose: Cereboost®, an American ginseng extract, has shown improved short-term memory and attention/alertness in healthy young and middle-aged individuals, potentially via modulation of the gut microbiome and upregulation of neurotransmitters such as acetylcholine. Here, we explored the effects of Cereboost® on cognition and mood in the first 6 h post intervention (acute), after 2 weeks daily supplementation (chronic), and whether 2 weeks daily supplementation altered the response to a single acute dose (acute-on-chronic). A concurrent in vitro study evaluated effects of repeated Cereboost® administration on human gut microbiota. Methods: Cognitive effects of Cereboost® were assessed using a double-blind, randomized, placebo-controlled clinical trial, with 61 healthy young adults. Modulation of the gut microbiome was concurrently modelled using the Simulator of the Human Microbial Ecosystem (SHIME®), using a young adult donor. Results: Consistent with previous findings, Cereboost® improved working memory and attention during the immediate postprandial period; effects that were amplified following two weeks' treatment (acute-on-chronic) compared to acute testing alone. Chronic supplementation improved cognition on an acetylcholine-sensitive attention task and improved mental fatigue and self-assurance aspects of mood. The parallel in vitro study revealed significantly increased acetate, propionate, and butyrate levels in simulated proximal and distal colon regions, linked with observed increases in Akkermansia muciniphila and Lactobacillus. Conclusion: This study confirmed the promising effects of Cereboost® on cognitive function and mood, while suggesting a possible link to alterations of the gut microbiome and modulation of acetylcholine. Further studies will be required to unravel the underlying mechanisms that are involved. Registration: The study was pre-registered at ClinicalTrials.gov on 6th July 2018 (Identifier: NCT03579095). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
118. Comparative analysis of the gut microbiota cultured in vitro using a single colon versus a 3-stage colon experimental design.
- Author
-
Firrman, Jenni, Liu, LinShu, Mahalak, Karley, Tanes, Ceylan, Bittinger, Kyle, Bobokalonov, Jamshed, Mattei, Lisa, Zhang, Huanjia, and Van den Abbeele, Pieter
- Subjects
- *
GUT microbiome , *SHORT-chain fatty acids , *COLON (Anatomy) , *EXPERIMENTAL design , *HUMAN microbiota - Abstract
The importance of the gut microbiota in human health and disease progression makes it a target for research in both the biomedical and nutritional fields. To date, a number of in vitro systems have been designed to recapitulate the gut microbiota of the colon ranging in complexity from the application of a single vessel to cultivate the community in its entirety, to multi-stage systems that mimic the distinct regional microbial communities that reside longitudinally through the colon. While these disparate types of in vitro designs have been employed previously, information regarding similarities and differences between the communities that develop within was less defined. Here, a comparative analysis of the population dynamics and functional production of short-chain fatty acids (SCFAs) was performed using the gut microbiota of the same donor cultured using a single vessel and a 3-stage colon system. The results found that the single vessel communities maintained alpha diversity at a level comparable to the distal regions of the 3-stage colon system. Yet, there was a marked difference in the type and abundance of taxa, particularly between families Enterobacteriaceae, Bacteroidaceae, Synergistaceae, and Fusobacteriaceae. Functionally, the single vessel community produced significantly less SCFAs compared to the 3-stage colon system. These results provide valuable information on how culturing technique effects gut microbial composition and function, which may impact studies relying on the application of an in vitro strategy. This data can be used to justify experimental strategy and provides insight on the application of a simplified versus complex study design. Key points: • A mature gut microbiota community can be developed in vitro using different methods. • Beta diversity metrics are affected by the in vitro culturing method applied. • The type and amount of short-chain fatty acids differed between culturing methods. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
119. A 4-strain probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis.
- Author
-
Ghyselinck, Jonas, Verstrepen, Lynn, Moens, Frédéric, Van den Abbeele, Pieter, Said, Jawal, Smith, Barry, Bjarnason, Ingvar, Basit, Abdul W., and Gaisford, Simon
- Subjects
- *
ULCERATIVE colitis , *PROBIOTICS , *GUT microbiome , *INFLAMMATORY bowel diseases , *BACTERIAL diversity , *WOUND healing - Abstract
Symprove, a multi-strain probiotic, has been shown to exert a mild anti-inflammatory effect in patients with ulcerative colitis (UC). We examined stool samples from 3 patients with UC in order to create microbiotas in an in-vitro gut model. The effects of Symprove on bacterial diversity and metabolic activity in the microbiotas was evaluated over 48 h. In addition, the influence of probiotic dosing on epithelial tight-junction integrity, production of inflammatory markers and wound healing were evaluated in cell culture models. The relative proportions of the main bacterial phyla in UC patients differed from those of healthy subjects studied previously; levels of Firmicutes were lowered and levels of Bacteroidetes were raised. Addition of Symprove changed the bacterial composition in the microbiotas over a 48 h period. Several other factors generally implicated in good gut health changed after dosing with probiotic; production of short chain fatty acids (SCFAs) and lactate was stimulated, levels of anti-inflammatory cytokines (IL-6, IL-10) increased, levels of pro-inflammatory cytokines and chemokines (MCP-1 and IL-8) decreased, epithelial tight junction integrity improved and wound healing occurred faster than a control. The results imply it is not the simple addition of probiotic bacteria that improves gut health. Rather, the probiotic bacteria generate lactate, which then stimulates growth of commensal gut bacteria, raising SCFA levels (particularly butyrate). The increased butyrate concentration positively influences inflammation response and time of wound healing. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
120. Serum-Derived Bovine Immunoglobulin Promotes Barrier Integrity and Lowers Inflammation for 24 Human Adults Ex Vivo.
- Author
-
Van den Abbeele P, Kunkler CN, Poppe J, Rose A, van Hengel IAJ, Baudot A, and Warner CD
- Subjects
- Humans, Cattle, Adult, Animals, Male, Female, Caco-2 Cells, Immunoglobulins, Colon microbiology, Colon metabolism, Colon drug effects, Inulin pharmacology, THP-1 Cells, Fermentation, Middle Aged, Prebiotics, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Intestinal Mucosa drug effects, Fatty Acids, Volatile metabolism, Gastrointestinal Microbiome drug effects, Inflammation
- Abstract
Serum-derived bovine immunoglobulin (SBI) prevents translocation and inflammation via direct binding of microbial components. Recently, SBI also displayed potential benefits through gut microbiome modulation. To confirm and expand upon these preliminary findings, SBI digestion and colonic fermentation were investigated using the clinically predictive ex vivo SIFR
® technology (for 24 human adults) that was, for the first time, combined with host cells (epithelial/immune (Caco-2/THP-1) cells). SBI (human equivalent dose (HED) = 2 and 5 g/day) and the reference prebiotic inulin (IN; HED = 2 g/day) significantly promoted gut barrier integrity and did so more profoundly than a dietary protein (DP), especially upon LPS-induced inflammation. SBI also specifically lowered inflammatory markers (TNF-α and CXCL10). SBI and IN both enhanced SCFA (acetate/propionate/butyrate) via specific gut microbes, while SBI specifically stimulated valerate/bCFA and indole-3-propionic acid (health-promoting tryptophan metabolite). Finally, owing to the high-powered cohort (n = 24), treatment effects could be stratified based on initial microbiota composition: IN exclusively stimulated (acetate/non-gas producing) Bifidobacteriaceae for subjects classifying as Bacteroides / Firmicutes -enterotype donors, coinciding with high acetate/low gas production and thus likely better tolerability of IN. Altogether, this study strongly suggests gut microbiome modulation as a mechanism by which SBI promotes health. Moreover, the SIFR® technology was shown to be a powerful tool to stratify treatment responses and support future personalized nutrition approaches.- Published
- 2024
- Full Text
- View/download PDF
121. Tomato seed extract promotes health of the gut microbiota and demonstrates a potential new way to valorize tomato waste.
- Author
-
Firrman J, Narrowe A, Liu L, Mahalak K, Lemons J, Van den Abbeele P, Baudot A, Deyaert S, Li Y, Yao Y, and Yu L
- Subjects
- Humans, Plant Extracts chemistry, Seeds chemistry, Antioxidants analysis, Prebiotics analysis, Gastrointestinal Microbiome, Solanum lycopersicum
- Abstract
The current effort to valorize waste byproducts to increase sustainability and reduce agricultural loss has stimulated interest in potential utilization of waste components as health-promoting supplements. Tomato seeds are often discarded in tomato pomace, a byproduct of tomato processing, yet these seeds are known to contain an array of compounds with biological activity and prebiotic potential. Here, extract from tomato seeds (TSE), acquired from pomace, was evaluated for their ability to effect changes on the gut microbiota using an ex vivo strategy. The results found that TSE significantly increased levels of the beneficial taxa Bifidobacteriaceae in a donor-independent manner, from a range of 18.6-24.0% to 27.0-51.6% relative abundance following treatment, yet the specific strain of Bifidobacteriaceae enhanced was inter-individually variable. These structural changes corresponded with a significant increase in total short-chain fatty acids, specifically acetate and propionate, from an average of 13.3 to 22.8 mmol/L and 4.6 to 7.4 mmol/L, respectively. Together, these results demonstrated that TSE has prebiotic potential by shaping the gut microbiota in a donor-independent manner that may be beneficial to human health. These findings provide a novel application for TSE harvested from tomato pomace and demonstrate the potential to further valorize tomato waste products., Competing Interests: No competing interest., (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
- Published
- 2024
- Full Text
- View/download PDF
122. Metagenomes and metagenome-assembled genomes from ex vivo fecal incubations of six unique donors.
- Author
-
Narrowe AB, Liu L, Lemons JMS, Firrman JA, Mahalak KK, Deyaert S, Baudot A, and Van den Abbeele P
- Abstract
We present a donor-specific collection of 78 metagenomes (13/donor) and 143 metagenome-assembled genomes (MAGs), representing the gut microbiomes of six healthy adult human donors. In addition to adding to the catalog of publicly available human gut MAGs, this resource permits a genome-resolved look into microbial co-occurrence across six individuals., Competing Interests: The authors S.D., A.B., and P.V.d.A. are employees of Cryptobiotix SA.
- Published
- 2024
- Full Text
- View/download PDF
123. Impact of Baizhu, Daqingye, and Hehuanhua extracts on the human gut microbiome.
- Author
-
Lemons JMS, Narrowe AB, Liu L, Firrman J, Mahalak KK, Van den Abbeele P, Baudot A, Deyaert S, Li Y, and Yu LL
- Subjects
- Humans, Medicine, Chinese Traditional, Gastrointestinal Microbiome, Drugs, Chinese Herbal pharmacology, Drugs, Chinese Herbal chemistry
- Abstract
Introduction: In traditional Chinese medicine, the rhizome of Atractylodes macrocephala (Baizhu), the leaves of Isatis indigotica (Daqingye), and the flowers of Albizia julibrissin (Hehuanhua) have been used to treat gastrointestinal illnesses, epidemics, and mental health issues. Modern researchers are now exploring the underlying mechanisms responsible for their efficacy. Previous studies often focused on the impact of purified chemicals or mixed extracts from these plants on cells in tissue culture or in rodent models., Methods: As modulation of the human gut microbiome has been linked to host health status both within the gastrointestinal tract and in distant tissues, the effects of lipid-free ethanol extracts of Baizhu, Daqingye, and Hehuanhua on the human adult gut microbiome were assessed using Systemic Intestinal Fermentation Research (SIFR
® ) technology (n=6)., Results and Discussion: Baizhu and Daqingye extracts similarly impacted microbial community structure and function, with the extent of effects being more pronounced for Baizhu. These effects included decreases in the Bacteroidetes phylum and increases in health-related Bifidobacterium spp. and short chain fatty acids which may contribute to Baizhu's efficacy against gastrointestinal ailments. The changes upon Hehuanhua treatment were larger and included increases in multiple bacterial species, including Agathobaculum butyriciproducens , Adlercreutzia equolifaciens , and Gordonibacter pamelaeae , known to produce secondary metabolites beneficial to mental health. In addition, many of the changes induced by Hehuanhua correlated with a rise in Enterobacteriaceae spp., which may make the tested dose of this herb contraindicated for some individuals. Overall, there is some evidence to suggest that the palliative effect of these herbs may be mediated, in part, by their impact on the gut microbiome, but more research is needed to elucidate the exact mechanisms., Competing Interests: Authors PV, AB, SD are employed by Cryptobiotix. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Lemons, Narrowe, Liu, Firrman, Mahalak, Van den Abbeele, Baudot, Deyaert, Li and Yu.)- Published
- 2023
- Full Text
- View/download PDF
124. Small intestine vs. colon ecology and physiology: Why it matters in probiotic administration.
- Author
-
Jensen BAH, Heyndrickx M, Jonkers D, Mackie A, Millet S, Naghibi M, Pærregaard SI, Pot B, Saulnier D, Sina C, Sterkman LGW, Van den Abbeele P, Venlet NV, Zoetendal EG, and Ouwehand AC
- Subjects
- Humans, Intestine, Small, Biological Transport, Feces, Colon, Probiotics
- Abstract
Research on gut microbiota has generally focused on fecal samples, representing luminal content of the large intestine. However, nutrient uptake is restricted to the small intestine. Abundant immune cell populations at this anatomical site combined with diminished mucus secretion and looser junctions (partly to allow for more efficient fluid and nutrient absorption) also results in intimate host-microbe interactions despite more rapid transit. It is thus crucial to dissect key differences in both ecology and physiology between small and large intestine to better leverage the immense potential of human gut microbiota imprinting, including probiotic engraftment at biological sensible niches. Here, we provide a detailed review unfolding how the physiological and anatomical differences between the small and large intestine affect gut microbiota composition, function, and plasticity. This information is key to understanding how gut microbiota manipulation, including probiotic administration, may strain-dependently transform host-microbe interactions at defined locations., Competing Interests: Declaration of interests A.C.O., M.N., B.P., D.S., L.G.W.S., and P.V.D.A. work full time for IFF, ADM, Yakult, Novozymes, Caelus Health, and Cryptobiotix respectively. These companies were not involved in carrying out this research., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
125. Bridging preclinical and clinical gut microbiota research using the ex vivo SIFR ® technology.
- Author
-
Van den Abbeele P, Deyaert S, Thabuis C, Perreau C, Bajic D, Wintergerst E, Joossens M, Firrman J, Walsh D, and Baudot A
- Abstract
Introduction: While modulation of the human adult gut microbiota is a trending strategy to improve health, the underlying mechanisms are poorly understood., Methods: This study aimed to assess the predictive value of the ex vivo , reactor-based, high-throughput SIFR
® (Systemic Intestinal Fermentation Research) technology for clinical findings using three structurally different prebiotics [inulin (IN), resistant dextrin (RD) and 2'-fucosyllactose (2'FL)]., Results: The key finding was that data obtained within 1-2 days were predictive for clinical findings upon repeated prebiotic intake over weeks: among hundreds of microbes, IN stimulated Bifidobacteriaceae , RD boosted Parabacteroides distasonis , while 2'FL specifically increased Bifidobacterium adolescentis and Anaerobutyricum hallii . In line with metabolic capabilities of these taxa, specific SCFA (short-chain fatty acids) were produced thus providing insights that cannot be obtained in vivo where such metabolites are rapidly absorbed. Further, in contrast to using single or pooled fecal microbiota (approaches used to circumvent low throughput of conventional models), working with 6 individual fecal microbiota enabled correlations that support mechanistic insights. Moreover, quantitative sequencing removed the noise caused by markedly increased cell densities upon prebiotic treatment, thus allowing to even rectify conclusions of previous clinical trials related to the tentative selectivity by which prebiotics modulate the gut microbiota. Counterintuitively, not the high but rather the low selectivity of IN caused only a limited number of taxa to be significantly affected. Finally, while a mucosal microbiota (enriched with Lachnospiraceae ) can be integrated, other technical aspects of the SIFR® technology are a high technical reproducibility, and most importantly, a sustained similarity between the ex vivo and original in vivo microbiota., Discussion: By accurately predicting in vivo results within days, the SIFR® technology can help bridge the so-called "Valley of Death" between preclinical and clinical research. Facilitating development of test products with better understanding of their mode of action could dramatically increase success rate of microbiome modulating clinical trials.Graphical Abstract., Competing Interests: PVdA, SD and AB are employees of Cryptobiotix. CT and CP are employees of Roquette, while EW and DB are employees of DSM. DW is employed by CosmosID. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Van den Abbeele, Deyaert, Thabuis, Perreau, Bajic, Wintergerst, Joossens, Firrman, Walsh and Baudot.)- Published
- 2023
- Full Text
- View/download PDF
126. Development of a reproducible small intestinal microbiota model and its integration into the SHIME ® -system, a dynamic in vitro gut model.
- Author
-
Deyaert S, Moens F, Pirovano W, van den Bogert B, Klaassens ES, Marzorati M, Van de Wiele T, Kleerebezem M, and Van den Abbeele P
- Abstract
The human gastrointestinal tract consists of different regions, each characterized by a distinct physiology, anatomy, and microbial community. While the colonic microbiota has received a lot of attention in recent research projects, little is known about the small intestinal microbiota and its interactions with ingested compounds, primarily due to the inaccessibility of this region in vivo . This study therefore aimed to develop and validate a dynamic, long-term simulation of the ileal microbiota using the SHIME
® -technology. Essential parameters were identified and optimized from a screening experiment testing different inoculation strategies, nutritional media, and environmental parameters over an 18-day period. Subjecting a synthetic bacterial consortium to the selected conditions resulted in a stable microbiota that was representative in terms of abundance [8.81 ± 0.12 log (cells/ml)], composition and function. Indeed, the observed community mainly consisted of the genera Streptococcus, Veillonella, Enterococcus, Lactobacillus , and Clostridium (qPCR and 16S rRNA gene targeted Illumina sequencing), while nutrient administration boosted lactate production followed by cross-feeding interactions towards acetate and propionate. Furthermore, similarly as in vivo , bile salts were only partially deconjugated and only marginally converted into secondary bile salts. After confirming reproducibility of the small intestinal microbiota model, it was integrated into the established M-SHIME® where it further increased the compositional relevance of the colonic community. This long-term in vitro model provides a representative simulation of the ileal bacterial community, facilitating research of the ileum microbiota dynamics and activity when, for example, supplemented with microbial or diet components. Furthermore, integration of this present in vitro simulation increases the biological relevance of the current M-SHIME® technology., Competing Interests: FM, MM, and TW are employees of ProDigest, that provides services to other companies using the model developed in this study. SD and PA were employees of ProDigest when this project was conducted. During the current project WP, Bv, and EK were employed by BaseClear, the company providing NGS services throughout the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Deyaert, Moens, Pirovano, van den Bogert, Klaassens, Marzorati, Van de Wiele, Kleerebezem and Van den Abbeele.)- Published
- 2023
- Full Text
- View/download PDF
127. Dynamic effects of probiotic formula ecologic®825 on human small intestinal ileostoma microbiota: a network theory approach.
- Author
-
Jansma J, Thome NU, Schwalbe M, Chatziioannou AC, Elsayed SS, van Wezel GP, van den Abbeele P, van Hemert S, and El Aidy S
- Subjects
- Adult, Humans, Propionates pharmacology, Enterobacteriaceae, Gastrointestinal Microbiome, Microbiota, Probiotics pharmacology
- Abstract
The gut microbiota plays a pivotal role in health and disease. The use of probiotics as microbiota-targeted therapies is a promising strategy to improve host health. However, the molecular mechanisms involved in such therapies are often not well understood, particularly when targeting the small intestinal microbiota. In this study, we investigated the effects of a probiotic formula (Ecologic®825) on the adult human small intestinal ileostoma microbiota. The results showed that supplementation with the probiotic formula led to a reduction in the growth of pathobionts, such as Enterococcaceae and Enterobacteriaceae , and a decrease in ethanol production. These changes were associated with significant alterations in nutrient utilization and resistance to perturbations. These probiotic mediated alterations which coincided with an initial increase in lactate production and decrease in pH were followed by a sharp increase in the levels of butyrate and propionate. Moreover, the probiotic formula increased the production of multiple N-acyl amino acids in the stoma samples. The study demonstrates the utility of network theory in identifying novel microbiota-targeted therapies and improving existing ones. Overall, the findings provide insights into the dynamic molecular mechanisms underlying probiotic therapies, which can aid in the development of more effective treatments for a range of conditions.
- Published
- 2023
- Full Text
- View/download PDF
128. Inclusion of small intestinal absorption and simulated mucosal surfaces further improve the Mucosal Simulator of the Canine Intestinal Microbial Ecosystem (M-SCIME™).
- Author
-
Verstrepen L, Van den Abbeele P, Pignataro G, Ribecco C, Gramenzi A, Hesta M, and Marzorati M
- Subjects
- Animals, Dogs, Intestinal Absorption, Intestine, Small, Gastrointestinal Microbiome, Microbiota, Probiotics
- Abstract
While a large set of in vitro models are available to study the effects of specific food ingredients (e.g. pre- and probiotics) on the human gut microbiome, the availability of such models for companion animals is limited. Since improving gut health of such animals is an emerging research field, the Simulator of the Canine Intestinal Microbial Ecosystem (SCIME™) was recently developed and validated with in vivo data. The current study presents a further improvement of this model by using an alternative method for feed preparation, i.e. by administering digestive enzymes to mimic upper gastro-intestinal digestion followed by a dialysis approach to mimic small intestinal absorption. As opposed to the previously implemented method, this resulted in a more optimal simulation of protein digestion and absorption. Further, upon entrance in the colon, increased production of the health-promoting butyrate and lower levels of Lactobacillus spp. and Bifidobacterium spp. were observed, which corresponded better with obtained in vivo data. A second model improvement consisted of the implementation of a mucosal environment to not only simulate luminal but also mucosal microbiota. In consistency with the human model for which this technology was previously validated, it was found that for all canine microbiota mucin beads were enriched with members of the Lachnospiraceae (~ Clostridium cluster XIVa), a family containing multiple well-known butyrate producers. The SCIME™ was thus upgraded to a so-called Mucosal SCIME™ (M-SCIME™). In conclusion, the current study presents improvements of the SCIME™, further increasing the relevance of obtained data with this in vitro model for dogs., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
129. Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease.
- Author
-
Ghyselinck J, Verstrepen L, Moens F, Van Den Abbeele P, Bruggeman A, Said J, Smith B, Barker LA, Jordan C, Leta V, Chaudhuri KR, Basit AW, and Gaisford S
- Abstract
We report here the potential role of a 4-strain probiotic suspension for use with patients with Parkinson's disease (PD). Stool samples from a group of three patients with diagnosed PD were used to create microbiotas in an in-vitro gut model. The effects of dosing with an oral probiotic suspension (Symprove) on bacterial composition and metabolic activity in the microbiotas was evaluated over 48 h and compared with healthy controls. Additionally, the effect of probiotic dosing on epithelial tight-junction integrity, production of inflammatory markers and wound healing were evaluated in cell culture models. In general, the relative proportions of the main bacterial phyla in the microbiotas of PD patients differed from those of healthy subjects, with levels of Firmicutes raised and levels of Bacteroidetes reduced. Dosing with probiotic resulted in a change in bacterial composition in the microbiotas over a 48 h period. Several other indicators of gut health changed upon dosing with the probiotic; production of short chain fatty acids (SCFAs) and lactate was stimulated, levels of anti-inflammatory cytokines (IL-6, IL-10) increased and levels of pro-inflammatory cytokines and chemokines (MCP-1 and IL-8) decreased. Tight junction integrity was seen to improve with probiotic dosing and wound healing was seen to occur faster than a control. The data suggest that if development and/or progression of PD is influenced by gut microbiota dysbiosis then supplementation of the diet with a properly formulated probiotic may be a useful adjunct to standard treatment in clinic., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
130. The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.
- Author
-
d'Enfert C, Kaune AK, Alaban LR, Chakraborty S, Cole N, Delavy M, Kosmala D, Marsaux B, Fróis-Martins R, Morelli M, Rosati D, Valentine M, Xie Z, Emritloll Y, Warn PA, Bequet F, Bougnoux ME, Bornes S, Gresnigt MS, Hube B, Jacobsen ID, Legrand M, Leibundgut-Landmann S, Manichanh C, Munro CA, Netea MG, Queiroz K, Roget K, Thomas V, Thoral C, Van den Abbeele P, Walker AW, and Brown AJP
- Subjects
- Candida albicans immunology, Candida albicans pathogenicity, Humans, Candidiasis immunology, Candidiasis microbiology, Host Microbial Interactions physiology, Microbial Interactions physiology
- Abstract
Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients., (© The Author(s) 2020. Published by Oxford University Press on behalf of FEMS.)
- Published
- 2021
- Full Text
- View/download PDF
131. A synbiotic concept containing spore-forming Bacillus strains and a prebiotic fiber blend consistently enhanced metabolic activity by modulation of the gut microbiome in vitro .
- Author
-
Duysburgh C, Van den Abbeele P, Krishnan K, Bayne TF, and Marzorati M
- Abstract
A standardized in vitro simulation of the human gastrointestinal tract (M-SHIME®) was used to assess the effect of repeated daily administration of a synbiotic formulation, containing five spore-forming Bacillus strains and a prebiotic fiber blend, on the microbial activity and composition of three simulated human subjects. Firstly, while confirming recent findings, deeper phylogenetic insight was obtained in the resident M-SHIME® microbiota, demonstrating that the model maintains a diverse and representative, colon region-specific luminal and mucosal microbial community. Supplementation of the synbiotic concept increased microbial diversity in the distal colon areas, whereas specific enhancement of Bacillaceae levels was observed in the ascending colon suggesting a successful engraftment of the Bacillus spores, which probably resulted in a stimulatory effect on, among others, Bifidobacteriaceae , Lactobacillaceae, Prevotellaceae , Tannerellaceae and Faecalibacterium prausnitzii contributing directly or indirectly to stimulation of acetate, propionate and butyrate production. When compared with a previous study investigating the Bacillus strains, the generated data suggest a synergistic effect on the intestinal microbiota for the synbiotic formulation. Given the fact that the probiotic strains have been shown to impact post-prandial metabolic endotoxemia in human individuals, it might be interesting to further investigate the efficacy of the synbiotic concept in protecting against obesity-related disorders.
- Published
- 2019
- Full Text
- View/download PDF
132. Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment.
- Author
-
Vermeiren J, Van den Abbeele P, Laukens D, Vigsnaes LK, De Vos M, Boon N, and Van de Wiele T
- Subjects
- Acyl Coenzyme A genetics, Acyl Coenzyme A metabolism, Adult, Aged, Butyrates metabolism, Clostridium growth & development, Coenzyme A-Transferases genetics, Coenzyme A-Transferases metabolism, Colitis, Ulcerative metabolism, Eubacterium growth & development, Fatty Acids, Volatile metabolism, Female, Gastrointestinal Tract microbiology, Humans, Intestinal Mucosa microbiology, Male, Middle Aged, Models, Biological, Clostridium physiology, Colitis, Ulcerative microbiology, Eubacterium physiology, Mucins metabolism
- Abstract
The mucus layer in the colon, acting as a barrier to prevent invasion of pathogens, is thinner and discontinuous in patients with ulcerative colitis (UC). A recent developed in vitro dynamic gut model, the M-SHIME, was used to compare long-term colonization of the mucin layer by the microbiota from six healthy volunteers (HV) and six UC patients and thus distinguish the mucin adhered from the luminal microbiota. Although under the same nutritional conditions, short-chain fatty acid production by the luminal communities from UC patients showed a tendency toward a lower butyrate production. A more in-depth community analysis of those microbial groups known to produce butyrate revealed that the diversity of the Clostridium coccoides/Eubacterium rectale and Clostridium leptum group, and counts of Faecalibacterium prausnitzii were lower in the luminal fractions of the UC samples. Counts of Roseburia spp. were lower in the mucosal fractions of the UC samples. qPCR analysis for butyryl-CoA:acetate CoA transferase, responsible for butyrate production, displayed a lower abundance in both the luminal and mucosal fractions of the UC samples. The M-SHIME model revealed depletion in butyrate producing microbial communities not restricted to the luminal but also in the mucosal samples from UC patients compared to HV., (© 2011 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
133. Incorporating a mucosal environment in a dynamic gut model results in a more representative colonization by lactobacilli.
- Author
-
Van den Abbeele P, Roos S, Eeckhaut V, MacKenzie DA, Derde M, Verstraete W, Marzorati M, Possemiers S, Vanhoecke B, Van Immerseel F, and Van de Wiele T
- Subjects
- Humans, Lactobacillus classification, Lactobacillus genetics, Lactobacillus isolation & purification, Models, Biological, Phylogeny, Intestinal Mucosa microbiology, Lactobacillus growth & development
- Abstract
To avoid detrimental interactions with intestinal microbes, the human epithelium is covered with a protective mucus layer that traps host defence molecules. Microbial properties such as adhesion to mucus further result in a unique mucosal microbiota with a great potential to interact with the host. As mucosal microbes are difficult to study in vivo, we incorporated mucin-covered microcosms in a dynamic in vitro gut model, the simulator of the human intestinal microbial ecosystem (SHIME). We assessed the importance of the mucosal environment in this M-SHIME (mucosal-SHIME) for the colonization of lactobacilli, a group for which the mucus binding domain was recently discovered. Whereas the two dominant resident Lactobacilli, Lactobacillus mucosae and Pediococcus acidilactici, were both present in the lumen, L. mucosae was strongly enriched in mucus. As a possible explanation, the gene encoding a mucus binding (mub) protein was detected by PCR in L. mucosae. Also the strongly adherent Lactobacillus rhamnosus GG (LGG) specifically colonized mucus upon inoculation. Short-term assays confirmed the strong mucin-binding of both L. mucosae and LGG compared with P.acidilactici. The mucosal environment also increased long-term colonization of L. mucosae and enhanced its stability upon antibiotic treatment (tetracycline, amoxicillin and ciprofloxacin). Incorporating a mucosal environment thus allowed colonization of specific microbes such as L. mucosae and LGG, in correspondence with the in vivo situation. This may lead to more in vivo-like microbial communities in such dynamic, long-term in vitro simulations and allow the study of the unique mucosal microbiota in health and disease., (© 2011 The Authors; Microbial Biotechnology © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.